rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
This study aims to determine the value of codon 72 missense polymorphic variant genotyping, TP53 R72P, as a prognostic factor in NSCLC patients.
|
29286914 |
2018 |
rs1131691014
|
|
|
0.070 |
GeneticVariation |
BEFREE |
This study aims to determine the value of codon 72 missense polymorphic variant genotyping, TP53 R72P, as a prognostic factor in NSCLC patients.
|
29286914 |
2018 |
rs878854066
|
|
|
0.070 |
GeneticVariation |
BEFREE |
This study aims to determine the value of codon 72 missense polymorphic variant genotyping, TP53 R72P, as a prognostic factor in NSCLC patients.
|
29286914 |
2018 |
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In summary, we found that the p53 p. Pro72Arg, MDM2 c.14 + 309T > G and MDM2 c.-461C > G polymorphisms are associated with toxicity risks following platinum-based chemotherapy treatment in advanced NSCLC patients.
|
25482940 |
2014 |
rs1131691014
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In summary, we found that the p53 p. Pro72Arg, MDM2 c.14 + 309T > G and MDM2 c.-461C > G polymorphisms are associated with toxicity risks following platinum-based chemotherapy treatment in advanced NSCLC patients.
|
25482940 |
2014 |
rs878854066
|
|
|
0.070 |
GeneticVariation |
BEFREE |
In summary, we found that the p53 p. Pro72Arg, MDM2 c.14 + 309T > G and MDM2 c.-461C > G polymorphisms are associated with toxicity risks following platinum-based chemotherapy treatment in advanced NSCLC patients.
|
25482940 |
2014 |
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
We evaluated seven single-nucleotide polymorphisms of six genes CDA Lys27Gln (A/C); CDA C435T; ERCC1 C118T; XRCC3 Thr241Met (C/T); XPD Lys751Gln (A/C); P53 Arg72Pro (G/C), and RRM1 C524T in 192 chemotherapy-naive patients with advanced NSCLC treated with cisplatin/gemcitabine-based regimen by TaqMan probe-based assays with 7300 Real-Time PCR System, using genomic DNA extracted from blood samples.
|
22052224 |
2011 |
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
This study investigated whether the functional polymorphisms in P53 pathway genes, P53 Arg72Pro (rs1042522), P73 G4C14-to-A4T14 (rs2273953 and rs1801173), and MDM2 T309G (rs2279744), alone or in combination, affect survival in advanced non-small cell lung cancer (NSCLC) patients.
|
21841506 |
2011 |
rs1131691014
|
|
|
0.070 |
GeneticVariation |
BEFREE |
We evaluated seven single-nucleotide polymorphisms of six genes CDA Lys27Gln (A/C); CDA C435T; ERCC1 C118T; XRCC3 Thr241Met (C/T); XPD Lys751Gln (A/C); P53 Arg72Pro (G/C), and RRM1 C524T in 192 chemotherapy-naive patients with advanced NSCLC treated with cisplatin/gemcitabine-based regimen by TaqMan probe-based assays with 7300 Real-Time PCR System, using genomic DNA extracted from blood samples.
|
22052224 |
2011 |
rs1131691014
|
|
|
0.070 |
GeneticVariation |
BEFREE |
This study investigated whether the functional polymorphisms in P53 pathway genes, P53 Arg72Pro (rs1042522), P73 G4C14-to-A4T14 (rs2273953 and rs1801173), and MDM2 T309G (rs2279744), alone or in combination, affect survival in advanced non-small cell lung cancer (NSCLC) patients.
|
21841506 |
2011 |
rs878854066
|
|
|
0.070 |
GeneticVariation |
BEFREE |
We evaluated seven single-nucleotide polymorphisms of six genes CDA Lys27Gln (A/C); CDA C435T; ERCC1 C118T; XRCC3 Thr241Met (C/T); XPD Lys751Gln (A/C); P53 Arg72Pro (G/C), and RRM1 C524T in 192 chemotherapy-naive patients with advanced NSCLC treated with cisplatin/gemcitabine-based regimen by TaqMan probe-based assays with 7300 Real-Time PCR System, using genomic DNA extracted from blood samples.
|
22052224 |
2011 |
rs878854066
|
|
|
0.070 |
GeneticVariation |
BEFREE |
This study investigated whether the functional polymorphisms in P53 pathway genes, P53 Arg72Pro (rs1042522), P73 G4C14-to-A4T14 (rs2273953 and rs1801173), and MDM2 T309G (rs2279744), alone or in combination, affect survival in advanced non-small cell lung cancer (NSCLC) patients.
|
21841506 |
2011 |
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The purpose of the study was to investigate whether polymorphisms of p53 codon 72 (Arg72Pro) and MDM2 SNP309 (309T>G) affect p53 expression and the clinical outcome of patients with advanced nonsmall cell lung cancer (NSCLC).
|
18618574 |
2008 |
rs1131691014
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The purpose of the study was to investigate whether polymorphisms of p53 codon 72 (Arg72Pro) and MDM2 SNP309 (309T>G) affect p53 expression and the clinical outcome of patients with advanced nonsmall cell lung cancer (NSCLC).
|
18618574 |
2008 |
rs878854066
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The purpose of the study was to investigate whether polymorphisms of p53 codon 72 (Arg72Pro) and MDM2 SNP309 (309T>G) affect p53 expression and the clinical outcome of patients with advanced nonsmall cell lung cancer (NSCLC).
|
18618574 |
2008 |
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Our results suggest that the genotype of the Arg72Pro polymorphism may modulate the frequency of TP53 mutations in non-small-cell lung cancer.
|
17932356 |
2007 |
rs1131691014
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Our results suggest that the genotype of the Arg72Pro polymorphism may modulate the frequency of TP53 mutations in non-small-cell lung cancer.
|
17932356 |
2007 |
rs878854066
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Our results suggest that the genotype of the Arg72Pro polymorphism may modulate the frequency of TP53 mutations in non-small-cell lung cancer.
|
17932356 |
2007 |
rs1042522
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
|
16499995 |
2006 |
rs1131691014
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
|
16499995 |
2006 |
rs878854066
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism.
|
16499995 |
2006 |
rs762846821
|
|
|
0.020 |
GeneticVariation |
BEFREE |
KRAS G12D and STK11 mutations confer poor prognoses for patients with KRAS-mutant NSCLC.
|
31200821 |
2019 |
rs762846821
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Using genetically engineered mouse models (GEMMs) for human non-small-cell lung cancer (NSCLC), we found that deletion of the essential autophagy gene, Atg7, in KRAS(G12D)-driven NSCLC inhibits tumor growth and converts adenomas and adenocarcinomas to benign oncocytomas characterized by the accumulation of respiration-defective mitochondria.
|
23959381 |
2013 |
rs1800372
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, we detected the rare R213R (rs1800372, minor allele frequency: 0.0054) polymorphism in 7.2% of the patients and are the first to show the significant association with TP53 mutations in non-small cell lung cancer adenocarcinoma patients (p = 0.003).
|
28240049 |
2017 |
rs12947788
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Interestingly, TP53 polymorphisms in intron 7 (rs12947788 and rs12951053) were more frequently identified in asbestos-exposed NSCLC (P = 0.046) and MPM patients than in unexposed patients (P < 0.001 and P = 0.012, respectively).
|
23435014 |
2013 |